First Daily GLP-1 Pill Approved: Wegovy Oral Achieves 17% Weight Loss in Trial
The MHRA’s landmark approval of oral semaglutide introduces a needle-free GLP-1 option for obesity, backed by a 17% weight-loss result in adherent patients. Healthcare providers must now navigate private-only access and patient education around strict dosing protocols.